On July 20, 2024, the China Foundation for Hepatitis Prevention and Control, together with the Chinese Center for Disease Control and Prevention, the Chinese Medical Association, and the Chinese Preventive Medicine Association, held the 2024 World Hepatitis Day Publicity Conference and the Hepatitis Elimination Action Conference in Beijing. At the meeting, Chang Jile, deputy director of the National Bureau of Disease Control and Prevention, introduced that the mainland adheres to a comprehensive prevention and control mechanism led by the party and government, coordinated by departments, mobilizes the society, and participates in the whole people, adheres to the principle of prevention first, combines prevention and treatment, and strengthens the process of eliminating the harm of hepatitis with the joint efforts of the whole society.
In the summary, Wang Yu, chairman of the China Hepatitis Prevention and Control Foundation, said that at present, the technology and drug conditions required to eliminate the harm of viral hepatitis in the mainland are available, and the cost is affordable. Now, we need to call on the whole society to take active action to advocate for hepatitis B screening and vaccination; expanding coverage of antiviral therapy for chronic hepatitis B; Implement standardized whole-process management of liver diseases, and actively promote early liver cancer surveillance in high-risk groups; Explore the inclusion of hepatitis B patient management in basic public health services, further promote the prevention and treatment of hepatitis in the mainland, and accelerate the elimination of the harm of hepatitis.
Experts call for the implementation of early liver cancer surveillance to reduce liver disease deaths
Hepatitis-cirrhosis-liver cancer is a three-step process of chronic liver disease, and only by curbing the progression of hepatitis can the occurrence of severe liver disease be reduced. The five-year survival rate for liver cancer patients in mainland China is less than 15%. Experts at the meeting called for strengthening multidisciplinary cooperation to promote the management of hepatitis patients throughout the course of the disease. Carry out early liver cancer surveillance in key populations such as patients with chronic viral hepatitis, early detection, early diagnosis and early treatment, and reduce the mortality rate of liver cancer.
"Regular monitoring is the key to improving the survival rate of liver cancer patients, and it is recommended to remind doctors and patients to strengthen the monitoring of liver cancer through information means, and patients with chronic hepatitis B should have AFP testing and ultrasound examination at least once every 6 months."
——Professor Jia Jidong
"The burden of advanced liver cancer is too high, and the most important thing is to detect liver cancer early."
——Professor Zhang Wenhong
"The risk of liver cancer in patients with chronic hepatitis B is 15-20 times higher than that of ordinary people, and different international liver disease professional organizations have recommended three programs for monitoring small liver cancer with ultrasound + blood."
——Professor Poon Kai-on
"Through non-invasive screening techniques, such as HBV RNA, GP73 and liver cancer (AFP, AFP-L3% and DCP), it can be detected and treated in time at the early stage of different liver diseases to reduce the occurrence of end-stage liver disease."
——Professor Zheng Sujun
"Japan uses AFP, AFP-L3 and DCP biomarker detection, combined with abdominal ultrasound examination, to carry out early liver cancer surveillance in high-risk groups, and timely take treatment interventions, effectively improving the survival rate of liver cancer patients."
——Prof. Niu Junqi, Prof. Xie Qing, Prof. Ding Huiguo, Prof. He Yingli
The above content is transferred from the official WeChat account of the China Hepatitis Prevention and Control Foundation: Eliminate Hepatitis and Take Positive Action - The 2024 World Hepatitis Day Publicity Conference and the Action Conference to Eliminate the Harm of Hepatitis were held in Beijing
"Liver Cancer Prevention and Health in China" large-scale public welfare activities,
Contribute to Healthy China 2030
In 2019, Hotgen Biotech and China Health Promotion Foundation established the "Special Fund for Liver Cancer Prevention and Control", and took this as a starting point to start the first public welfare "small goal" - the Liver Cancer Prevention and Health China Ten-Year Action. In the past five years, under the guidance of relevant government units and the coordination of all social forces, the public welfare project has built a moat for early cancer screening of Chinese people with the blessing of fist products comparable to the international frontier. It has organized a number of public welfare donation projects in Hunan, Jilin, Annex, Guangxi, Shaanxi, Anhui and other places, and carried out large-scale offline free clinic activities covering the whole country through the annual 3.18 National Love Liver Day and 7.28 World Hepatitis Day, providing free accurate screening services for more than 100,000 high-risk groups, and cooperating with local medical institutions to organize online/offline disease lectures, patient education and other popular science education that benefits millions of people, which has had a positive social impact. 2024 is the first year of the second five-year "Liver Cancer Prevention and Health China Tour", with the new five years and new actions, with cutting-edge technology, blockbuster innovative products and the strength of the public welfare circle, the Liver Cancer Prevention and Health China Tour will create more value at the public and patient levels, create huge benefits at the social level, and approach the goal of Healthy China 2030: the overall 5-year survival rate of cancer in mainland China is not less than 46.6% with public welfare potential.
On July 2, the National Administration for Disease Control and Prevention released the theme of the 2024 "World Hepatitis Day" "Positive Action to Eliminate Hepatitis". In order to further respond to the call of "Healthy China Action (2019-2030)", during the 14th "World Hepatitis Day", the large-scale public welfare screening activity of "Healthy China Tour for Liver Cancer Prevention and Control" supported by the Liver Cancer Prevention and Control Special Fund was simultaneously launched in 21+ provinces across the country, and the liver cancer early screening technology used in this activity - three liver cancer (AFP, AFP-L3% and DCP) was listed as a routine early screening marker for high-risk groups of liver cancer by the Japan Society of Hepatology, and regular monitoring of high-risk groups was recommended. Through offline activities, nearly 10,000 high-risk groups of liver cancer were provided with free liver cancer early screening techniques such as three types of liver cancer and GP73, and combined with expert free consultation, science popularization and education, etc., so that more medical workers can pay attention to liver cancer prevention and control, further improve the concept of early screening of the population, and improve the early diagnosis rate and survival rate of liver cancer.
In the process of achieving the goal of 46.6% five-year survival rate for cancer patients in mainland China, public welfare projects coordinated by government units, medical institutions, social groups, and public welfare organizations will become a new focus and play an important role.
"Liver Cancer Prevention and Treatment Healthy China Tour"
Public welfare activities (partial)
